Pluvicto Archives -

It has been announced today that Novartis’ Pluvicto (lutetium vipivotide tetraxetan) has shown statistically significant and clinically meaningful

Novartis’ Pluvicto presents survival benefit for castration-resistant prostate cancer

https://pharmaphorum.com/news/novartis-pluvicto-presents-survival-benefit-for-castration-resistant-prostate-cancer/

With a reorganisation of Novartis now nearing completion, the Swiss pharma group is laying out its plans for

Revamped Novartis highlights top R&D programmes at management update

https://pharmaphorum.com/news/revamped-novartis-highlights-top-rd-programmes-at-management-update/

Ben Hargreaves examines what advantages radiopharmaceuticals offer in the treatment of cancer and why there has been interest

Are radiopharmaceuticals the next breakthrough in oncology?

https://pharmaphorum.com/oncology/are-radiopharmaceuticals-the-next-breakthrough-in-oncology/

Novartis has secured its first approval in Europe for prostate cancer radioligand therapy Pluvicto, getting a green light

Novartis’ Pluvicto gets first European approval in GB

https://pharmaphorum.com/news/novartis-pluvicto-gets-first-european-approval-in-gb/

Novartis has shut down production of its radioligand therapies – one of its key growth areas – at

Manufacturing foul-up hits Novartis’ radioligand business

https://pharmaphorum.com/news/manufacturing-foul-up-hits-novartis-radioligand-business/

The UK regulator has said eligible patients with prostate cancer will get early access to a radioligand therapy

UK grants early access to Novartis’ prostate cancer radioligand

https://pharmaphorum.com/news/uk-grants-early-access-to-novartis-prostate-cancer-radioligand/

Novartis has been steadily investing in radiopharmaceuticals over the last few years, and one of those deals has

Novartis gets first OK for radioligand Pluvicto in prostate cancer

https://pharmaphorum.com/news/novartis-gets-first-ok-for-radioligand-pluvicto-in-prostate-cancer/

Pluvicto